BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

562 related articles for article (PubMed ID: 24607556)

  • 1. Collateral damage of nonhematopoietic tissue by hematopoiesis-specific T cells results in graft-versus-host disease during an ongoing profound graft-versus-leukemia reaction.
    van der Zouwen B; Kruisselbrink AB; Frederik Falkenburg JH; Jedema I
    Biol Blood Marrow Transplant; 2014 Jun; 20(6):760-9. PubMed ID: 24607556
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alloreactive effector T cells require the local formation of a proinflammatory environment to allow crosstalk and high avidity interaction with nonhematopoietic tissues to induce GVHD reactivity.
    van der Zouwen B; Kruisselbrink AB; Jordanova ES; Rutten CE; von dem Borne PA; Falkenburg JH; Jedema I
    Biol Blood Marrow Transplant; 2012 Sep; 18(9):1353-67. PubMed ID: 22796533
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD4 Donor Lymphocyte Infusion Can Cause Conversion of Chimerism Without GVHD by Inducing Immune Responses Targeting Minor Histocompatibility Antigens in HLA Class II.
    van Balen P; van Bergen CAM; van Luxemburg-Heijs SAP; de Klerk W; van Egmond EHM; Veld SAJ; Halkes CJM; Zwaginga JJ; Griffioen M; Jedema I; Falkenburg JHF
    Front Immunol; 2018; 9():3016. PubMed ID: 30619360
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multicenter analyses demonstrate significant clinical effects of minor histocompatibility antigens on GvHD and GvL after HLA-matched related and unrelated hematopoietic stem cell transplantation.
    Spierings E; Kim YH; Hendriks M; Borst E; Sergeant R; Canossi A; Oudshoorn M; Loiseau P; Dolstra H; Markiewicz M; Leffell MS; Pereira N; Kircher B; Turpeinen H; Eliaou JF; Gervais T; Laurin D; Enczmann J; Martinetti M; Thomson J; Oguz F; Santarone S; Partanen J; Siekiera U; Alessandrino EP; Kalayoglu S; Brand R; Goulmy E
    Biol Blood Marrow Transplant; 2013 Aug; 19(8):1244-53. PubMed ID: 23756210
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selective depletion of alloreactive T lymphocytes using patient-derived nonhematopoietic stimulator cells in allograft engineering.
    Nonn M; Herr W; Khan S; Todorova M; Link I; Thies J; Distler E; Kaltwasser M; Hoffmann J; Huber C; Hartwig UF
    Transplantation; 2008 Nov; 86(10):1427-35. PubMed ID: 19034014
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Donor T cells administered over HLA class II barriers mediate antitumor immunity without broad off-target toxicity in a NOD/scid mouse model of acute leukemia.
    Stevanović S; Nijmeijer BA; van Schie ML; Salvatori DC; Maas S; Griffioen M; Falkenburg JH
    Biol Blood Marrow Transplant; 2013 Jun; 19(6):867-75. PubMed ID: 23500532
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HA-1H T-Cell Receptor Gene Transfer to Redirect Virus-Specific T Cells for Treatment of Hematological Malignancies After Allogeneic Stem Cell Transplantation: A Phase 1 Clinical Study.
    van Balen P; Jedema I; van Loenen MM; de Boer R; van Egmond HM; Hagedoorn RS; Hoogstaten C; Veld SAJ; Hageman L; van Liempt PAG; Zwaginga JJ; Meij P; Veelken H; Falkenburg JHF; Heemskerk MHM
    Front Immunol; 2020; 11():1804. PubMed ID: 32973756
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Target antigens for graft-versus-host disease (GVHD) and graft-versus-leukemia/tumor (GVL/T)].
    Tanaka J
    Nihon Rinsho; 2003 Sep; 61(9):1512-9. PubMed ID: 14515717
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunomonitoring of graft-versus-host minor histocompatibility antigen correlates with graft-versus-host disease and absence of relapse after graft.
    Laurin D; Hannani D; Pernollet M; Moine A; Plumas J; Bensa JC; Cahn JY; Garban F
    Transfusion; 2010 Feb; 50(2):418-28. PubMed ID: 19843288
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Graft-versus-leukemia and graft-versus-host reactions after donor lymphocyte infusion are initiated by host-type antigen-presenting cells and regulated by regulatory T cells in early and long-term chimeras.
    Xia G; Truitt RL; Johnson BD
    Biol Blood Marrow Transplant; 2006 Apr; 12(4):397-407. PubMed ID: 16545723
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of 4 new HLA-DR-restricted minor histocompatibility antigens as hematopoietic targets in antitumor immunity.
    Stumpf AN; van der Meijden ED; van Bergen CA; Willemze R; Falkenburg JH; Griffioen M
    Blood; 2009 Oct; 114(17):3684-92. PubMed ID: 19706888
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective graft-versus-leukemia depends on magnitude and diversity of the alloreactive T cell response.
    van Bergen CA; van Luxemburg-Heijs SA; de Wreede LC; Eefting M; von dem Borne PA; van Balen P; Heemskerk MH; Mulder A; Claas FH; Navarrete MA; Honders WM; Rutten CE; Veelken H; Jedema I; Halkes CJ; Griffioen M; Falkenburg JH
    J Clin Invest; 2017 Feb; 127(2):517-529. PubMed ID: 28067665
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Post-hematopoietic cell transplantation control of graft-versus-host disease by donor CD425 T cells to allow an effective graft-versus-leukemia response.
    Jones SC; Murphy GF; Korngold R
    Biol Blood Marrow Transplant; 2003 Apr; 9(4):243-56. PubMed ID: 12720217
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Possible involvement of allogeneic antigens recognised by donor-derived CD4 cytotoxic T cells in selective GVL effects after stem cell transplantation of patients with haematological malignancy.
    Matsushita M; Yamazaki R; Ikeda H; Mori T; Sumimoto H; Fujita T; Okamoto S; Ikeda Y; Kawakami Y
    Br J Haematol; 2006 Jan; 132(1):56-65. PubMed ID: 16371020
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of Biological Relevant Minor Histocompatibility Antigens within the B-lymphocyte-Derived HLA-Ligandome Using a Reverse Immunology Approach.
    Hombrink P; Hassan C; Kester MG; Jahn L; Pont MJ; de Ru AH; van Bergen CA; Griffioen M; Falkenburg JH; van Veelen PA; Heemskerk MH
    Clin Cancer Res; 2015 May; 21(9):2177-86. PubMed ID: 25589627
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ex vivo detection of CD8 T cells specific for H-Y minor histocompatibility antigens in allogeneic hematopoietic stem cell transplant recipients.
    Nakamura R; La Rosa C; Tsai W; Lacey SF; Srivastava T; Seidel A; Senitzer D; Forman SJ; Diamond DJ
    Transpl Immunol; 2014 May; 30(4):128-35. PubMed ID: 24582729
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Minor antigens - major impact. The role of minor histocompatibility antigens in allogeneic hematopoietic stem cell transplantation].
    Hudecek M; Bartsch K; Tschiedel S; Niederwieser D
    Dtsch Med Wochenschr; 2008 Jul; 133(28-29):1511-6. PubMed ID: 18597211
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Minor histocompatibility antigens as targets of graft-versus-leukemia reactions.
    Falkenburg JH; Marijt WA; Heemskerk MH; Willemze R
    Curr Opin Hematol; 2002 Nov; 9(6):497-502. PubMed ID: 12394171
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Minor histocompatibility antigens: past, present, and future.
    Spierings E
    Tissue Antigens; 2014 Oct; 84(4):374-60. PubMed ID: 25262921
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patient HLA-DP-specific CD4+ T cells from HLA-DPB1-mismatched donor lymphocyte infusion can induce graft-versus-leukemia reactivity in the presence or absence of graft-versus-host disease.
    Rutten CE; van Luxemburg-Heijs SA; Halkes CJ; van Bergen CA; Marijt EW; Oudshoorn M; Griffioen M; Falkenburg JH
    Biol Blood Marrow Transplant; 2013 Jan; 19(1):40-8. PubMed ID: 22871556
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.